XT
ZNTL icon

XTX Topco’s Zentalis Pharmaceuticals ZNTL Stock Holding History

XTX Topco’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.41M Sell
289,693
-32,814
-10% -$131K 0.02% 1470
2026
Q1 		$755K Sell
322,507
-254,200
-44% -$656K 0.01% 1664
2025
Q4 		$779K Buy
576,707
+28,078
+5% +$40.9K 0.02% 1215
2025
Q3 		$828K Buy
548,629
+283,800
+107% +$425K 0.04% 695
2025
Q2 		$307K Buy
264,829
+140,433
+113% +$185K 0.01% 1413
2025
Q1 		$198K Buy
124,396
+1,408
+1% +$3.04K 0.01% 1708
2024
Q4 		$373K Sell
122,988
-71,074
-37% -$233K 0.03% 1029
2024
Q3 		$714K Buy
194,062
+15,597
+9% +$56.7K 0.05% 590
2024
Q2 		$730K Buy
178,465
+167,854
+1,582% +$1.87M 0.06% 484
2024
Q1 		$167K Buy
+10,611
New +$146K 0.02% 1230
2023
Q4 		– Sell
-19,008
Closed -$381K – 2235
2023
Q3 		$381K Buy
+19,008
New +$482K 0.07% 571
2023
Q2 		– Sell
-21,215
Closed -$365K – 1911
2023
Q1 		$365K Buy
+21,215
New +$430K 0.08% 498
2022
Q4 		– Sell
-9,655
Closed -$209K – 1567
2022
Q3 		$209K Buy
+9,655
New +$264K 0.05% 753

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

XTX Topco's ZNTL Position: Q2 2026 in Review

XTX Topco reduced its Zentalis Pharmaceuticals (ZNTL) stake by 10% in Q2 2026, selling an estimated $131K and leaving 289,693 shares worth $1.41M. The position accounts for 0.02% of the portfolio, ranked #1470.

XTX Topco first reported a position in ZNTL in Q3 2022 and has held it in 13 quarters since. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • XTX Topco held 289,693 shares of Zentalis Pharmaceuticals worth $1.41M as of Q2 2026.
  • XTX Topco sold 32,814 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $131K.
  • Zentalis Pharmaceuticals made up 0.02% of XTX Topco's portfolio in Q2 2026, its #1470 holding.
  • XTX Topco first reported a position in Zentalis Pharmaceuticals in Q3 2022 and has held it in 13 quarters since.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.